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The Emergency Depart-
ment (ED) at Baystate 
Medical Center treats 
more than 1,500 patients 
with complications 
related to Opioid Use 
Disorder (OUD) annually, 
a diagnosis that involves 
a problematic pattern of 
repetitive opioid use that 
can cause serious harm to 
the individual. To address 
this OUD epidemic, in 
2018, Baystate Medi-
cal Center’s ED began 
providing buprenorphine 
(Suboxone) treatment for 
OUD with prompt follow 
up and outpatient referral.
Currently, “nearly 100% 
of Baystate’s Emergency 
Department (ED) attend-
ing physicians have been 
waivered to administer 
and prescribe buprenor-
phine,” says Dr. William 
Soares, an IHDPS Fellow 
and Assistant Professor of 
Emergency Medicine at 
UMass Medical School-
Baystate. “In addition, 
in coordination with 
community partners like 
Tapestry and Behavioral 
Health Network (BHN), 
we can schedule prompt 
outpatient follow up 
appointments, much more 
rapidly than if the patient 
tried to navigate the 
healthcare system alone.” 
Dr. Soares is one of many 
ED providers who see 
the devastating impact of 
the opioid epidemic on 
patients’ lives.
Baystate Health is one 
of five hospital systems 
involved in the EMBED 
trial, a NIH funded 
research study (EMBED 
stands for EMergency 
Department-Initiated 
BuprenorphinE for Opioid 
Use Disorder) that has the 
goal of increasing use of 
buprenorphine from the 
ED by improving efficiency 
in ordering, documenting, 
and obtaining follow up. 
Participation in the trial is 
helping Baystate Medical 
Center to streamline the 
ordering process for ED 
providers to prescribe 
buprenorphine in the ED. 
The project collaborates 
with TechSpring and 
Baystate IT to develop 
an enhanced electronic 
ordering system that 
helps busy emergency 
physicians determine and 
deliver the best treatments 
for patients with OUD. 
“In the ED, we most 
commonly treat patients 
who have experienced an 
opioid overdose,” explains 
Dr. Soares. “The rates 
of opioid overdose are 
especially high in western 
Massachusetts because of 
the increased prevalence 
of fentanyl in the heroin 
supply in our region. Fen-
tanyl is a much stronger 
opioid than heroin; when 
it is mixed with heroin, it is 
nearly impossible to know 
the amount or strength of 
the drug.”
“OUD can impact any-
one,” continues Dr. Soares. 
“It does not follow racial, 
ethnic or socioeconomic 
boundaries. In the ED, 
we treat many patients’ 
OUD who may not 
normally seek healthcare 
resources,” including:
- After an opioid 
overdose when a friend or 
family member has called 
911 for help.
- An individual who 
wants help to stop using 
opioids and does not 
know where to go.
- A patient with a 
Opioid forum held at UMass Amherst
On Friday, September 6th, The Massachusetts Health 
Policy Forum hosted “Addressing the Opioid Crisis 
in Small and Rural Communities in Western Mas-
sachusetts.” The forum focused on the impact of the 
opioid crisis in western Massachusetts and the social/
economic consequences on employers and small and 
rural communities. Unique challenges and innovative 
solutions were highlighted during the program.  
The program began with Philip W. Johnston, Chair-
man of The Massachusetts Health Policy Forum. A 
video welcome from Sen. Ed Markey came next. Sen. 
Markey said “the opioid crisis is a multifaceted problem 
that will take a lot of time to solve…I look forward to 
ending this crisis once and for all...connecting people 
to treatment is only part of the equation.” 
Dr. Mark A. Keroack, President and CEO of Baystate 
Health, said that our system has “certainly felt the 
impact of the opioid crisis.” He also mentioned that 
“in these challenges lie our strengths...that is our best 
hope to turn this epidemic around.”
Dr. Peter D. Friedmann, Chief Research Officer at 
Baystate Health and Associate Dean for Research at 
UMass Medical School-Baystate, spoke about strong 
community coalitions and research projects taking 
place to help the crisis. 
This work is supported through the Blue Cross Blue 
Shield of Massachusetts Foundation, the University of 
Massachusetts Amherst School of Public Health and 
Health Sciences, RIZE Massachusetts Foundation, and 
Baystate Health. 
Dr. Mark A. Keroack, President and CEO of Baystate Health, speaking 
at the forum on September 6th.
Baystate’s Emergency Department 
responds to the opioid crisis
Bill Soares, MD of the Emergency 
Department.
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Baystate’s Investigational Pharmacy: 
a key to our clinical trials
Baystate’s Investigational Pharmacy 
is primarily responsible for providing 
patients with their research medications, 
whether they are IV fluids, hormone 
replacements, statins, or antibiotics. Ger-
ald “Jerry” Korona, RPh, is at the center 
of this operation. Serving as the Clinical 
Research Pharmacist since May 1998, 
Korona has been instrumental in the 
research program at Baystate; whether 
it’s his work in research pharmacy 
services, assisting residents in training 
opportunities, ordering/taking inventory 
of the pharmaceuticals, or his 17 years of 
service on the Baystate IRB (he started 
in 2002 and recently took on the Vice 
Chair role for IRB #1). He spends part of 
his day screening patients to see who 
may be eligible to participate in one of 
Baystate’s numerous clinical trials. 
“Part of our job at the Clinical Research 
Pharmacy, in addition to providing medi-
cations, is to give patients an opportunity 
to try something that has not yet been 
tested and customize what works best 
for them,” explains Korona. “Sometimes 
I have to mix drugs for our patients to 
meet their different treatment goals. This 
is helping us make strides in research 
that may benefit society one day.” He is 
also involved in Baystate’s emergency 
use submissions, works with sponsors 
for clinical trials, and has seen numerous 
teams through FDA audits.
“I’m the go-to person between 
patients and research staff,” he says, col-
laborating with numerous research physi-
cians throughout the institution. Much 
of his clinical care research revolves 
around cancer trials at Baystate. “Cancer 
studies are a little different,” he says. The 
eligibility window for cancer trials can be 
very narrow. Korona is part of the team 
that helps find trial participants at the 
right time. “We look at [drugs in] cancer 
studies as another option for patients in 
addition to their regular care.” 
Korona is a prior recipient of the 
Outstanding Clinical Research Support 
Award, which recognizes a person who 
takes action to solve systems issues that 
influence the conduct of clinical research 
at Baystate. He was part of the team 
which established Baystate’s participa-
tion in the ARDS Network for acute respi-
ratory distress. In 2009, The National 
Heart, Lung, and Blood Institute’s ARDS 
Network Data and Safety Monitoring 
Board recognized the Baystate Medi-
cal Center Clinical Center for superior 
performance which included recognition 
for “outstanding quality” service. 
“After 21 years here in the Clinical 
Research Pharmacy, I have learned a lot; 
not only about what I do but the impact 
we can make in patients’ lives with 
research,” he says. “I have seen a lot of 
small miracles, and we give patients an 
opportunity at life.”
(Above left) Gerald “Jerry” Korona, RPh, is the Clinical Research Pharmacist at Baystate Health. (Above right) 
A look inside of the Baystate Clinical Pharmacy.
Select Recent Awards
New Faces of Research
Briana Jurkowski 
Clinical Research 
Assistant II
IHDPS
Elizabeth Mutti
IRB Coordinator
IRB/HRPP
Victoria Cobb
Clinical Research 
Coordinator II
Clinical Trials Office
Karen Riska
Clinical Research 
Coordinator II
IHDPS
Lizbeth Del-Toro Mejias
Clinical Research 
Coordinator II
Office of Research
Taylar Clark 
Clinical Research 
Assistant II
IHDPS
Kyle McAnally
Clinical Research 
Assistant II
IHDPS
(Continued from page 1)
STEPHEN BOOS, MD, Project 
LAUNCH, MA Dept. of Public 
Health (DPH)
MAURA BRENNAN, MD, Geri-
atrics Workforce Enhancement 
Program 2, HRSA
MAUREEN DESABRAIS, FY18 
Intensive correctional health link-
age services, MA Dept. Of Public 
Health (DPH)
PETER FRIEDMANN, MD, Mas-
sachusetts Justice Community 
Opioid Innovation Network, Nat. 
Inst. on Drug Abuse
PETER FRIEDMANN, MD, 
DISCERNNE UH3, Nat. Inst. on 
Drug Abuse
SARAH HAESSLER, MD, FY18 
Ebola Predaredness, MA Dept. 
of Public Health (DPH)
AMIR LOTFI, MD, STEMICool 
Pilot Trial: A Multicenter, Prospec-
tive, Randomized-Controlled Trial 
to Access Cooling as an Adjunc-
tive Therapy to Percutaneous 
Intervention in Patients with 
Acute Myocardial Infarction, Zoll 
Circulation, Inc.
TIMOTHY MADER, MD, A 
contemporary subgroup analysis 
of cooling after non-shockable 
cardiac arrest: Insights from a 
large registry, Nat. Heart Lung 
Blood Inst.
TASHANNA MYERS, MD,
TESARO 4010-03-001 / ENGOT 
EN-6 / GOG-3031: A phase 
3, randomized, double-blind, 
multicenter study of dostarlimab 
(TSR-042) plus carboplatin-
paclitaxel versus placebo 
plus carboplatin-paclitaxel in 
patients with recurrent or primary 
advanced endometrial cancer, 
Tesaro, Inc. 
BARRY SARVET, MD, MCPAP 
Medical Director FY20, Beacon 
Health Options
MARK TIDSWELL, MD, A 
Prospective, Multicenter, Ran-
domized, Open-Label Study to 
Evaluate the Efficacy and Safety 
of PMX Cartridge in Addition 
to Standard Medical Care for 
Patients with Endotoxemic Septic 
Shock, Spectral Medical, Inc.
complication or injury from injecting drugs, including 
serious bacterial infections. Patients who inject drugs 
may inadvertently inject bacteria into their skin and 
blood. This may be from reusing the same needle, mix-
ing heroin with non-sterile water, or not wiping skin with 
alcohol before injecting. 
“For some patients, the ED serves as low-barrier 
entrance into OUD treatment,” he explains. “We are 
always open and able to connect people to the right 
treatment options.”
Finally, in collaboration with ED nursing staff, Baystate 
Medical Center’s ED is working to prevent injection-
related complications by providing harm reduction 
education and resources for our patients. 
“OUD is a chronic illness; we expect that, even 
patients in treatment may still relapse,” adds Dr. Soares. 
“However, even a single relapse can lead to a deadly 
overdose or a life-threatening infection. By helping our 
patients understand ways to keep themselves safe, such 
as educating about infection risks or providing Narcan to 
reverse an overdose, we may help to save lives.” 
The Innovator |  3
Breast cancer trials at Baystate Health
Notable Recent Published Papers
Contact Baystate’s Health Science Library for more information at libraryinfo.bhs.org/home
A Home-Based Study 
to Enhance Activity in 
Breast Cancer Survivors
Lead Researcher: Grace 
Makari-Judson, MD
Comparison of Axillary 
Lymph Node Dissection 
With Axillary Radia-
tion for Patients With 
Node-Positive Breast 
Cancer Treated With 
Chemotherapy
Lead Researcher: Seth 
Kaufman, MD
Docetaxel and Cyclo-
phosphamide Compared 
to Anthracycline-Based 
Chemotherapy in Treat-
ing Women With HER2-
Negative Breast Cancer
Lead Researcher: Grace 
Makari-Judson, MD
Doxorubicin Hydrochlo-
ride, Cyclophosphamide, 
and Paclitaxel With or 
Without Beva-
cizumab in 
Treating 
Patients 
With 
Lymph 
Node-
Positive or 
High-Risk, 
Lymph Node-
Negative 
Breast 
Cancer 
Lead 
Researcher: 
John 
McCann, MD
Doxorubicin and 
Cyclophosphamide Plus 
Paclitaxel With or Without 
Trastuzumab in Treating 
Women With Node-Pos-
itive Breast Cancer That 
Overexpresses HER2
Lead Researcher: Grace 
Makari-Judson, MD
ER Reactivation 
Therapy for Breast 
Cancer (POLLY)
Lead Researcher: 
Grace Makari-
Judson, MD
Letrozole 
in Treating 
Postmeno-
pausal Women 
Who Have Received 
Hormone Therapy for 
Hormone Receptor-Posi-
tive Breast Cancer
Lead Researcher: Grace 
Makari-Judson, MD
Pembrolizumab in Treat-
ing Patients With Triple-
Negative Breast Cancer
Lead Researcher: Grace 
Makari-Judson, MD
Radiation Therapy With 
or Without Optional 
Tamoxifen in Treating 
Women With Ductal 
Carcinoma in Situ
Lead Researcher: Grace 
Makari-Judson, MD
S1207 Hormone Therapy 
With or Without Everoli-
mus in Treating Patients 
With Breast Cancer (e3)
Lead Researcher: Grace 
Makari-Judson, MD
Standard or Comprehen-
sive Radiation Therapy 
in Treating Patients With 
Early-Stage Breast Can-
cer Previously Treated 
With Chemotherapy and 
Surgery
Lead Researcher: Seth 
Kaufman, MD
Creation of breast 
research registry
Lead Researcher: Grace 
Makari-Judson, MD
Hormone Therapy With 
or Without Combination 
Chemotherapy in Treat-
ing Women Who Have 
Undergone Surgery for 
Node-Negative Breast 
Cancer (The TAILORx 
Trial)
Lead Researcher: Grace 
Makari-Judson, MD
September Office of Research Town 
Hall: screening and discussion of 
the film Three Identical Strangers
The September 4th “Movie Night” for Office of Research 
staff featured popcorn, ice cream, and a screening of the 
2018 film Three Identical Strangers. A discussion of the film 
followed.
Three Identical Strangers is a compelling documentary 
about a set of American triplets, born in 1961, that raises 
disturbing ethical questions about human subjects research. 
The story provides a cautionary tale that the pursuit of 
scientific knowledge — and the attendant fame that new 
discoveries may bring — can blind investigators to the harm 
that they are causing their subjects. Despite contemporary 
ethical guidelines, we need to remain vigilant because these 
perils cannot be eliminated completely. The film is available 
on Hulu and Amazon Prime. 
(L-R) Meng-Shiou Shieh, PhD and Penelope S. Pekow, PhD; Elizabeth 
Mutti, Vera Postell, and Laura Henderson.
Back row (L-R): Victoria Cobb, Ali Griffin, and Scott Ouellette. Front row 
(L-R): Jenn Pacheco, Chris Lorenz, and Carol Lovewell.
Learn more at baystatehealth.org/patients/learn-about-clinical-trials.
Park SE, Grogan CM, Mosley 
JE, Humphreys K, Pollack HA, 
Friedmann PD. Correlates of 
Patient-Centered Care Practices 
at U.S. Substance Use Disorder 
Clinics. Psychiatr Serv. 2019 
Sep 10.
Cama S, Knee A, Sarvet B. 
Impact of Child Psychiatry Access 
Programs on Mental Health Care 
in Pediatric Primary Care: Mea-
suring the Parent Experience. 
Psychiatr Serv. 2019 Sep 25.
Stewart JM, Shaban MA, Fialkoff 
T, Tuma-Marcella B, Visintainer P, 
Terilli C, Medow MS. Mechanisms 
of tilt-induced vasovagal syn-
cope in healthy volunteers and 
postural tachycardia syndrome 
patients without past history 
of syncope. Physiol Rep. 2019 
Aug;7(13):e14148.
Orthopoulos G, Grant HM, 
Sharma P, Thompson E, 
Romanelli JR. S054: incidence 
and management of jejunojejunal 
intussusception after Roux-en-Y 
gastric bypass: a large case 
series. Surg Endosc. 2019 Aug 5.
Atreya AR, Priya A, Pack QR, 
Pekow PS, Stefan M, Lagu T, 
Lotfi AS, Lindenauer PK. Use 
and Outcomes Associated With 
Perioperative Amiodarone in Car-
diac Surgery. J Am Heart Assoc. 
2019 Aug 6;8(15):e009892.
Medow MS, Guber K, Chokshi 
S, Terilli C, Visintainer P, 
Stewart JM. The Benefits of 
Oral Rehydration on Orthostatic 
Intolerance in Children with 
Postural Tachycardia Syndrome. 
J Pediatr. 2019 Aug 9. pii: 
S0022-3476(19)30893-5.
Becker TK, Gul SS, Cohen SA, 
Maciel CB, Baron-Lee J, Murphy 
TW, Youn TS, Tyndall JA, Gibbons 
C, Hart L, Alviar-Restrepo CL; 
Florida Cardiac Arrest Resource 
Team. Public perception towards 
bystander cardiopulmonary 
resuscitation. Emerg Med J. 2019 
Aug 31.
Schoenfeld EM, Probst MA, 
Quigley DD, St Marie P, Nayyar 
N, Sabbagh SH, Beckford T, 
Kanzaria HK. Does Shared 
Decision-Making actually occur 
in the ED? Looking at it from 
the patients’ perspective. Acad 
Emerg Med. 2019 Aug 29.
Lagu T, Haskell J, Cooper E, 
Harris DA, Murray A, Gardner RL. 
Physician Beliefs About Online 
Reporting of Quality and Experi-
ence Data. J Gen Intern Med. 
2019 Aug 28.
Andrews C, Pollack A, Abraham 
A, Grogan C, Bersamira C, 
D’Aunno T, Friedmann PD. 
Medicaid coverage in substance 
use disorder treatment after 
the affordable care act. J Subst 
Abuse Treat. 2019 Jul;102:1-7.
O’Sullivan KF, Kashef MA, Knee 
AB, Roseman AS, Pekow PS, 
Stefan MS, Shieh MS, Pack 
QR, Lindenauer PK, Lagu T. 
Examining the “Repletion Reflex”: 
The Association between Serum 
Potassium and Outcomes in 
Hospitalized Patients with Heart 
Failure. J Hosp Med. 2019 Jul 
24;14:E1-E8.
Reuser AJJ, van der Ploeg AT, 
Chien YH, Llerena J Jr, Abbott 
MA, Clemens PR, Kimonis VE, 
Leslie N, Maruti SS, Sanson BJ, 
Araujo R, Periquet M, Toscano 
A, Kishnani PS; Pompe Registry 
Sites. GAA Variants and Pheno-
types Among 1079 Patients with 
Pompe Disease: Data from the 
Pompe Registry. Hum Mutat. 2019 
Jul 24.
Tiwary AK, Greco B, Richardson 
MW. Ectopic ACTH Syndrome 
in a Child With Abdominal Ewing 
Sarcoma: A Rare Paraneoplastic 
Phenomenon. J Pediatr Hematol 
Oncol. 2019 Jul 23.
LaValley G, Storer A, Szalai H, 
Farah M, Pack QR. A Motiva-
tional Telephone Intervention to 
Reduce Early Dropouts in Car-
diac Rehabilitation: A FEASIBIL-
ITY PILOT STUDY. J Cardiopulm 
Rehabil Prev. 2019 Jul 22.
Shami A, Brennan M, Marie 
PS, Lindenauer PK, Stefan MS. 
The association of cognitive 
impairment as screened by 
the Mini-Cog with long term 
post-hospitalization outcomes. 
Arch Gerontol Geriatr. 2019 Jul 
18;85:103916.
Goff SL, Unruh ML, Klingensmith 
J, Eneanya ND, Garvey C, Ger-
main MJ, Cohen LM. Advance 
care planning with patients on 
hemodialysis: an implementation 
study. BMC Palliat Care. 2019 Jul 
26;18(1):64.
DeJoy SA, Bohl MG, Mahoney 
K, Blake C. Estimating the Finan-
cial Impact of Reducing Primary 
Cesareans. J Midwifery Womens 
Health. 2019 Jul 28.
4 | The Innovator
We are interested in ensuring that Baystate employees and patients 
(and their families) are aware of the important research that goes on at 
Baystate and how it contributes to better patient care. The Innovator 
welcomes feedback and story ideas. Contact Allison Litera at allison.
litera@baystatehealth.org to submit yours.
Meet the Researcher
Name: Grace 
Makari-Judson, 
MD
Title/Academic 
Rank: Professor 
of Medicine,
UMMS-Baystate;
Co-Director,
the Rays of 
Hope Center for 
Breast Cancer 
Research;
Chair, Baystate 
Health Breast 
Network and 
Baystate 
Regional 
Cancer 
Program.
Number of years at Baystate: 30 years
What got you interested in research overall? Part of 
being a cancer specialist is trying to connect molecular 
findings to clinical applications. Although we usually think of 
translational research as the bench findings informing the 
clinic, I like to focus on how clinical observations can inform 
laboratory directions.
What is your area of research? I am the principal 
investigator for breast cancer clinical trials. I co-direct, with 
Joe Jerry, PhD, the Rays of Hope Center for Breast Cancer 
Research, which is how translational research comes into 
play. We developed a Breast Research Registry, now with 
over 1,000 participants, that links clinical information with 
tissue to serve as a resource for investigators. Most recently, 
we started the Metastatic Breast Cancer Registry to explore 
predictors of response to therapy.
How do you see your research improving care for 
patients? Clinical trials have provided our patients with 
opportunities to receive new treatments before they 
become mainstream. The translational research, for example 
our NIH grant to study estrogen and the environment, will 
hopefully contribute to our knowledge about what causes 
breast cancer. 
Favorite research projects? One of my areas of interest is 
weight change in women following a diagnosis of breast 
cancer. This has led to collaborations with UMass Amherst 
investigators interested in metabolism, exercise and 
survivorship issues.
Do you have any awards? The awards that have meant 
the most to me reflect my impact on the community in 
influencing women’s health and women in the sciences.  
Examples include the Pioneer Valley Women of Vision 
Award and the Bay Path Women Leaders Hall of Fame. 
In 2013, I was awarded the honorary degree, Doctor of 
Humane Letters, and delivered the commencement address 
at Bay Path University.  
What do you like the most about your job? The people 
I work with, the patients I am privileged to care for, and 
having the support of our community through Rays of Hope. 
It is extraordinary to be able to say that our community is 
cheering us on and has raised over four million dollars to 
support breast cancer research.  
What do you do to unwind outside of work? With two sons 
on the West Coast and two sons on the East Coast, traveling 
is a must. Wherever we are, my husband and I like to try out 
new cuisines and get inspired. To balance out the gourmet 
meals, I enjoy yoga, tennis, golf and being outdoors.
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Dr. Makari-Judson at the Rays of Hope Walk.
Collaborative opportunities with UMass 
Amherst’s Institute for Applied Life Sciences
Peter Reinhart, PhD, Founding Director of the Institute for Applied 
Life Sciences at UMass Amherst.
The Institute for 
Applied Life Sciences 
(IALS) is a product-
focused, interdisciplinary, 
collaborative, and entre-
preneurial translational 
research center at UMass 
Amherst. It is a close 
partner of Baystate Health 
and UMMS-Baystate, as 
well as the Pioneer Valley 
Life Sciences Institute 
(PVLSI).
“Faculty at UMass 
Amherst committed 
to multi-disciplinary 
research with industrial 
partners and collabora-
tors on campus, at UMass 
Medical School, at UMass 
Medical School-Baystate, 
and other institutions are 
welcome to collaborate,” 
says Peter Reinhart, PhD, 
founding director of the 
IALS. “The creation of 
the IALS in 2015 was 
enabled by a significant 
investment from the Mas-
sachusetts Life Science 
Center (MLSC), and was 
prompted by the desire 
to have an organized unit 
on the Amherst campus 
enabling translational 
research projects. Our 
goal is to bring groups 
together to collaborate 
toward meaningful out-
comes and meet the com-
munity’s broad needs in 
all areas overlapping with 
human health and well-
being.” The IALS works 
with industry partners to 
combine academic inno-
vation with an industry-
like focus on delivering 
commercially significant 
product candidates, ser-
vices, and technologies 
over a defined timeline. 
Undergraduates as well 
as graduate students 
at UMass Amherst also 
have the opportunity to 
participate in IALS activi-
ties such as experiential 
learning opportunities 
within IALS Core Equip-
ment Facilities.  
The IALS is organized 
into three large centers: 
the Center for Bioactive 
Delivery (developing reli-
able models for drug/car-
rier systems), the Center 
for Personalized Health 
Monitoring (advancing 
precision health monitor-
ing), and the Models to 
Medicine Center (translat-
ing fundamental science 
into new targets, leads, 
and disease models). 
“Across the three 
Centers, each led by a 
faculty director, there are 
more than 250 faculty-led 
research groups from 
more than 25 different 
departments on the 
UMass Amherst cam-
pus,” says Dr. Reinhart.  
“These are organized into 
research themes, with 
diverse capabilities and of 
interest to industry as well 
as government organiza-
tions. Being part of an 
IALS center provides 
access to fellow faculty, 
resources, collabora-
tions, and potentially 
industry partnerships 
more aligned with your 
research.” 
IALS supports 30 
centralized Core Facilities 
that enable a wide range 
of research projects for 
students, faculty, and 
industry/government 
partners. Some examples 
of IALS’s core facilities 
are device fabrication, 
exercise intervention and 
outcomes, human motion, 
and sleep monitoring. 
These facilities are 
equally accessible to 
academic, government, 
and industry collabora-
tors. In close proximity to 
these core facilities are 
“Collaboratories” – lab 
space available to indus-
try partners and start-up 
companies to work 
closely with and along-
side IALS faculty. 
IALS also maintains a 
diverse start-up commu-
nity, ranging from “idea 
to Series A” companies. 
Part of this Innovation & 
Entrepreneurship capac-
ity includes the availability 
of “Virtual C-Suites” that 
help start-up companies 
achieve key milestones 
and increase company 
value. IALS leadership 
and faculty are very inter-
ested in clinically-relevant 
ventures and anticipate 
greater collaboration with 
Baystate faculty, espe-
cially as projects move 
toward human studies.
To explore how IALS 
can help you advance 
your ideas or goals, 
please reach out to ialsdi-
rector@umass.edu.
